MT3/QR2 melatonin binding site does not use melatonin as a substrate or a co-substrate

被引:30
作者
Boutin, Jean A. [1 ]
Marcheteau, Estelle [1 ]
Hennig, Philippe
Moulharat, Natacha [1 ]
Berger, Sylvie [1 ]
Delagrange, Philippe [2 ]
Bouchet, Jean-Paul
Ferry, Gilles [1 ]
机构
[1] Inst Rech Servier, F-78290 Croissy Sur Seine, France
[2] Inst Rech Servier, Dept Sci Expt, F-92150 Suresnes, France
关键词
co-substrate; melatonin; MT3; nuclear magnetic resonance; quinone reductase 2; redox; substrate;
D O I
10.1111/j.1600-079X.2008.00631.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Quinone reductase 2 (QR2, E.C. 1.10.99.2) is implicated in cell reactive oxygen species production. The catalytic activity of this enzyme is inhibited by 1 mu M of melatonin. QR2 was identified as the third melatonin binding site (MT3). It is of major importance to understand the exact roles of melatonin and QR2 in oxidative stress. A fascinating possibility that melatonin could serve as a co-substrate or substrate of QR2 was hypothesized recently. In the current investigation, nuclear magnetic resonance studies of the QR2 catalytic reaction were performed, the results led us to conclude that, whatever the conditions, melatonin is not cleaved off to form N1-acetyl-N2-formyl-5-methoxykynurenine by a catalytically active QR2, very strongly indicating that melatonin is neither a substrate nor a co-substrate of this enzyme. Further studies are needed in order to better understand the relationship between MT3/QR2, melatonin and redox status of the cells, in order to better explain the anti-oxidant activities of melatonin at pharmacological concentrations (> 1 mu M).
引用
收藏
页码:524 / 531
页数:8
相关论文
共 40 条
  • [21] An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes:: Glutathione S-transferase M1 and quinone oxidoreductase 1 and 2
    Harada, S
    Fujii, C
    Hayashi, A
    Ohkoshi, N
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 288 (04) : 887 - 892
  • [22] Administration measurement of urinary melatonin:: A useful tool for monitoring serum melatonin after its oral administration
    Kovács, J
    Brodner, W
    Kirchlechner, V
    Arif, T
    Waldhauser, F
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (02) : 666 - 670
  • [23] Synthesis of nitroindole derivatives with high affinity and selectivity for melatoninergic binding sites MT3
    Leclerc, V
    Yous, S
    Delagrange, P
    Boutin, JA
    Renard, P
    Lesieur, D
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (09) : 1853 - 1859
  • [24] ENZYMATIC OXIDATION OF SOME NON-PHOSPHORYLATED DERIVATIVES OF DIHYDRONICOTINAMIDE
    LIAO, S
    WILLIAMSASHMAN, HG
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1961, 4 (03) : 208 - +
  • [25] Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity
    Long, DJ
    Iskander, K
    Gaikwad, A
    Arin, M
    Roop, DR
    Knox, R
    Barrios, R
    Jaiswal, AK
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (48) : 46131 - 46139
  • [26] MA X, 2006, ENDOCRINOLOGY, V149, P1969
  • [27] Molecular pharmacology of the ovine melatonin receptor:: comparison with recombinant human MT1 and MT2 receptors
    Mailliet, F
    Audinot, V
    Malpaux, B
    Bonnaud, A
    Delagrange, P
    Migaud, M
    Barrett, P
    Viaud-Massuard, MC
    Lesieur, D
    Lefoulon, F
    Renard, P
    Boutin, JA
    [J]. BIOCHEMICAL PHARMACOLOGY, 2004, 67 (04) : 667 - 677
  • [28] Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme
    Mailliet, F
    Ferry, G
    Vella, F
    Berger, S
    Cogé, F
    Chomarat, P
    Mallet, C
    Guénin, SP
    Guillaumet, G
    Viaud-Massuard, MC
    Yous, S
    Delagrange, P
    Boutin, JA
    [J]. BIOCHEMICAL PHARMACOLOGY, 2005, 71 (1-2) : 74 - 88
  • [29] Organs from mice deleted for NRH:quinone oxidoreductase 2 are deprived of the melatonin binding site MT3
    Mailliet, F
    Ferry, G
    Vella, F
    Thiam, K
    Delagrange, P
    Boutin, JA
    [J]. FEBS LETTERS, 2004, 578 (1-2) : 116 - 120
  • [30] The potential of melatonin in reducing morbidity-mortality after craniocerebral trauma
    Maldonado, M. D.
    Murillo-Cabezas, F.
    Terron, M. P.
    Flores, L. J.
    Tan, D. X.
    Manchester, L. C.
    Reiter, R. J.
    [J]. JOURNAL OF PINEAL RESEARCH, 2007, 42 (01) : 1 - 11